What is Agamree (vamorolone) for?

Agamree (vamorolone) is a medicine prescribed for the treatment of pediatric (2 years and older) and adult patients with Duchenne muscular dystrophy (DMD) ^[1].

Agamree is available as an oral suspension (40 mg/mL)^[1].

How does Agamree (vamorolone) work?

Agamree (vamorolone) is a novel medicine that works similarly to common corticosteroids but in a safer way. The active ingredient, vamorolone, is a dissociative corticosteroid, which binds to the glucocorticoid receptor and works against inflammation.

The exact mechanism by which Agamree works for the alleviation of Duchenne symptoms is not clear. However, clinicial results show that it helps patients stand up quicker and walk better ^[2].

Where has Agamree (vamorolone) been approved?

Agamree (vamorolone) is currently only approved by theFDA in the USA ^[1]. The CHMP has recommended granting Agamree marketing authorization in the EU as well ^[2]. However, this is not officially the case yet.

References:

1. HIGHLIGHTS OF PRESCRIBING INFORMATION. FDA, 2 October 2023.
2. Agamree: Pending EC decision | European Medicines Agency. European Medicines Agency, 13 October 2023.